Omeros Corporation OMER today
announced that the Company's OMS824 Investigational New Drug Application (IND)
has been cleared by the U.S. Food and Drug Administration (FDA). With this
clearance, Omeros may commence enrollment in its Phase 1 clinical trial
evaluating OMS824, the Company's lead compound from its phosphodiesterase 10
(PDE10) program for schizophrenia and other cognitive disorders.
OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain
linked to a wide range of diseases that affect cognition, including
schizophrenia and Huntington's disease. The planned Phase 1 dose-ranging
study will evaluate the drug's safety, tolerability and pharmacokinetics in
healthy subjects, and Omeros expects clinical data before year end.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in